Trials / Active Not Recruiting
Active Not RecruitingNCT05399992
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
VICTORION REAL: An International Prospective Real-world Study to Evaluate the LDL-C changE and Adherence to incLisiran in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 847 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical practice.
Detailed description
Patients will be enrolled over a period of 23 months, and followed for up to 24 months to assess for study outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Inclisiran | Prospective observational study. There is no treatment allocation. Patients who are eligible to receive inclisiran will be enrolled into this study. |
Timeline
- Start date
- 2022-09-12
- Primary completion
- 2026-10-05
- Completion
- 2026-10-05
- First posted
- 2022-06-01
- Last updated
- 2026-02-03
Locations
40 sites across 8 countries: Austria, China, Israel, Malaysia, Saudi Arabia, Switzerland, United Arab Emirates, United Kingdom
Source: ClinicalTrials.gov record NCT05399992. Inclusion in this directory is not an endorsement.